Dr. Glenn Jaffe, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 416
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NC license 38097
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 416
- Services billed
- 2,473
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 853 | 396 |
| Imaging of retina | 815 | 378 |
| Extended exam of the back part of the eye with optic nerve drawing | 648 | 352 |
| Injection of drug into eye | 110 | 31 |
| 2d ultrasound scan of eye tissue and structures | 84 | 37 |
| Photography of the retina | 69 | 52 |
| Exam of visual field with extended testing | 24 | 14 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 21 | 19 |
| New patient complete exam of visual system | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Durham, NC | 238 |
| Ketorolac Tromethamine Other prescribers in Durham, NC | 220 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Durham, NC | 135 |
| Brimonidine Tartrate Other prescribers in Durham, NC | 80 |
| Timolol Maleate Other prescribers in Durham, NC | 71 |
| Prednisone Other prescribers in Durham, NC | 44 |
| Latanoprost Other prescribers in Durham, NC | 31 |
| Dorzolamide Hcl Other prescribers in Durham, NC | 23 |
| Bromfenac Sodium | 16 |
| Atropine Sulfate | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $2,280 in total to this clinician.
| Ocular Therapeutix, Inc. | $2,000 |
|---|---|
| Apellis Pharmaceuticals, Inc. | $133 |
| Ani Pharmaceuticals, Inc. | $122 |
| Biocryst Pharmaceuticals, Inc. | $24.59 |
| Consulting Fee | $2,000 |
|---|---|
| Food and Beverage | $280 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ocular Therapeutix, Inc. Feb 2, 2025 | Consulting Fee | $2,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 6 companies. The companies reported $6,494,133 in research payments for these studies, mostly to the institutions running them.
- Phase 2 study to investigate RO7200220 in diabetic macular edema
Roche Tcrc, Inc. - A phase iii study to investigate RO7200220 in patients with uveitic macular edema
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME
Roche Tcrc, Inc. - Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - Faricimab RO6867461 in patients with polypoidal choroidal vasculopathy
F. Hoffmann-la Roche AG - A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)
Genentech, Inc. - MAD to assess the safety tolerability and PK PD in nAMD patients
Roche Tcrc, Inc. - A phase iii multicenter observation comparator study of the efficacy safety and pharmacokinetics
Genentech, Inc. - Constance Faricimab in nAMD patients
Hoffmann-la Roche Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.